text_1: Novartis's new treatment for hives outperforms Xolair in trials.
text_2: Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives.